Search This Blog

Wednesday, July 4, 2018

Glaxo gets target lifts from Barclays, Deutsche Bank on growth expectations


FTSE 100 pharmaceutical group GlaxoSmithKline PLC (LON:GSK) has had its target price lifted by both Barclays and Deutsche Bank as both banks predicted upgrades to its earnings forecasts.
At Deutsche Bank, analysts upped their target to 1,525p from 1,420p while raising their earnings per share (EPS) forecasts by 6-7% on the back of foreign exchange weighting and the timing of the launch of GSKs Advair drug, which is expected from the fourth quarter of 2018.
They added that an update from the new head of research and development at GSK, Hal Baron, would also provide investors with insight into the future direction of the company, as well as an updated list of key pipeline assets, particularly plans for the firms oncology and immune-inflammation portfolios.
Meanwhile, Barclays analysts upped their target price to 1,750p from 1,700p, with the companys launch of its Shingrix shingles product playing out more favourably than expected.
They added that margin improvement was expected and a core EPS of over 120p was feasible.

Genmab Progress Triggers Milestone Payment to Seattle Genetics


Genmab A/S (Nasdaq Copenhagen: GEN) announced today that it will pay a milestone payment of USD 7 million to Seattle Genetics, Inc. (Nasdaq: SGEN) following progress in the HuMax-AXL-ADC development program.
The milestone payment was triggered by the initiation of expansion cohorts in the ongoing Phase I/II trial in solid tumors. Genmab originally licensed Seattle Genetics’ADC technology in September 2014, in order to combine it with Genmab’s proprietary HuMax-AXL antibody to target multiple tumor types.
‘This milestone payment marks the rapid progress of the development program for HuMax-AXL-ADC and we very much look forward to seeing data from this program in the future,’ said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. ‘This is the second development interaction we have with Seattle Genetics, who are experts in the field of antibody-drug conjugates. The licensing deal for the use of their ADC technology in our proprietary HuMax-AXL-ADC program allows us to pursue our goal of developing truly differentiated cancer therapeutics whilst retaining maximal ownership of our therapeutic products.’

HuMax-AXL-ADC is an ADC targeted to AXL, a signaling molecule expressed on many solid cancers and implicated in tumor biology. HuMax-AXL-ADC is in Phase I/II clinical development for seven different solid tumors: ovarian, cervical, endometrial, thyroid, non-small cell lung cancer (NSCLC), melanoma, and sarcoma. HuMax-AXL-ADC is fully owned by Genmab and the ADC technology used with HuMax-AXL-ADC was licensed from Seattle Genetics.

Alder Presents New Data on Efficacy in Phase 3 Trial for Chronic Migraine


Alder BioPharmaceuticals, Inc.(NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, announced today new six-month data from its PROMISE 2 Phase 3 clinical trial in patients with chronic migraine following a second quarterly infusion of eptinezumab.
The data show that patients experienced a reduction of 8.8 monthly migraine days (MMDs) from baseline following the second quarterly infusion of 300 mg of eptinezumab. These results demonstrate a further numerical improvement in efficacy over the first infusion which resulted in a reduction from baseline of 8.2 MMDs in this trial. Eptinezumab is Alder’s lead investigational product candidate for migraine prevention targeting calcitonin gene-related peptide (CGRP). Detailed results will be presented today at the 60th AHS Annual Scientific Meeting in San Francisco, CA.
‘These data further add to the significant body of clinical evidence supporting eptinezumab’s encouraging clinical profile and reinforce our belief in the value it may provide to patients, if approved’ said Robert Azelby, chief executive officer of Alder. ‘The robust efficacy shown over the two quarterly infusions of eptinezumab in chronic migraine patients continues to support eptinezumab’s potential as an important treatment option for patients living with this debilitating condition.’

Zeiss Ups Revenue Outlook


ZEISS, a technology enterprise operating in the fields of optics and optoelectronics, issued the following news release:
Carl Zeiss Meditec (ISIN: DE0005313704) has achieved revenue of approximately EUR 926 million in the first nine months of fiscal year 2017/18, based on preliminary data. This corresponds to revenue growth of approximately 7% vs. the previous year’s value of EUR 864.7 million. After adjustment for currency effects1), growth amounted to around 12 %.
For the fiscal year 2017/18, Carl Zeiss Meditec now expects revenue of between EUR 1,250 to EUR 1,300 million (previously: EUR 1,230 to EUR 1,280 million).
At this point in time, further financial information is not yet available. The 9-months quarterly statement for fiscal year 2017/18 will be published on August 10, 2018.

Dubai regulator probes private equity firm Abraaj over alleged mismanagement

gulator is investigating allegations of mismanagement at private equity firm Abraaj, which is on the verge of financial collapse after a scandal over its use of investor money, two sources familiar with the matter said.

The Dubai Financial Services Authority (DFSA) has interviewed the firm’s founder, Arif Naqvi, and other senior executives in the past few months as part of the probe, the sources said.
The DFSA declined to comment. Abraaj said in a statement discussions between it and the regulator were “ongoing.”
“The DFSA is kept apprised of developments in the overall Abraaj Group and has our full co-operation on all relevant matters,” Abraaj said.
“While we do not comment on confidential discussions with our regulators, we are highly focused on strengthening our corporate governance and internal controls.”
A third source said Abraaj co-chief executives Omar Lodhi and Selcuk Yorgancioglu were among those questioned by the regulator.
There was no immediate comment from Naqvi or his legal representative. There was also no immediate comment from Lodhi. Yorgancioglu referred a Reuters request for comment to Abraaj.
The investigation heaps more pressure on Abraaj which is trying to sell its investment management business to Colony Capital following a dispute with some of its investors over the use of money in a $1 billion healthcare fund.
This erupted late last year, when investors including the Bill & Melinda Gates Foundation and the International Finance Corp made allegations that Abraaj mishandled their money in the healthcare fund. Abraaj has denied misusing the funds.
The allegations triggered a solvency crisis at the fund, the biggest buyout fund in Middle East and North Africa.
After halting fund raising activities and shaking up management, Abraaj last month filed for provisional liquidation in the Cayman Islands as it seeks an agreement with creditors and is selling parts of its businesses.
Summary findings of a review by Deloitte, appointed by Abraaj to audit its operations, said that a cash shortage at the firm led it to dip into investor funds.
Deloitte said on June 4 there was no evidence of embezzlement or misappropriation, but highlighted a lack of “adequate governance” and “overall weakness” at Abraaj.
In a statement on June 21, the DFSA had said it would be “discussing various matters with the Joint Provisional Liquidators of Abraaj Holdings and Abraaj Investment Management Limited and would continue to work toward safeguarding the interests of investors.”
DFSA has the power to fine or ban individuals from working in financial services within the Dubai International Financial Centre (DIFC) and has in the past imposed penalties for rule breaches. For companies, that can lead to a fine or even a suspension from operating in the center.
Abraaj has a regulated entity, Abraaj Capital, in the DIFC.
In its statement, Abraaj said it was premature to speculate on actions that the regulator may or may not consider.
“We believe these are decisions best communicated by the regulator in the fullness of time and early speculation is unhelpful to the process,” the statement said.
The affair has raised concerns in the finance industry that Dubai’s reputation as a major financial center could suffer.
Dubai’s main stock market index <.DFMGI> is down 15 percent so far this year, making it one of the worst performing in the region. The market has been partly affected by the Abraaj situation as well as weakness in the property sector.
“It is easy to fault regulators and auditors in retrospect,” said Richard Segal, senior analyst at Manulife Asset Management, adding that it was not easy to detect mismanagement.
“One might also argue that the investor oversight that brought these issues into the open might prove to be timely.”

A Cardio Routine That Prevents Injuries


This cardio burner will also help prevent injury, says Chris Heuisler, global runWestin concierge for Westin Hotels and Resorts. Do 8 reps per move and repeat the circuit for 20 minutes.
1Alternating Crab Reach
cardio moves for runners
MATT RAINEY
Sit with palms and feet flat, fingertips pointed back. Drive hips up and reach right arm over head to left side. Return to start; repeat on other side for 1 rep.
2Plank With Knee-Drive
cardio moves for runners
MATT RAINEY
Start in a high plank. Keeping abs engaged tight, explosively drive left knee to right elbow. Return to start; quickly repeat on other side for 1 rep.
3Side Lunge and Balance
cardio moves for runners
MATT RAINEY
From standing, step right foot out into a lunge, keeping left leg straight. Drive off right foot to return to start, hovering right foot next to left; hold 1 beat. Do reps; switch legs.
4Lateral Pushup
cardio moves for runners
MATT RAINEY
Start in high plank. Move left hand and foot to the left, then bring right hand and foot to meet. Do a pushup. Move right hand and foot to right; follow with left hand and foot. Do a pushup. That’s 1 rep.
5Squat-Cross-Punch
cardio moves for runners
MATT RAINEY
Squat low with back flat, chest raised. As you rise up, rotate hips to the left and punch with right fist. Rotate back to center; repeat on other side for 1 rep.

6Skaters
cardio moves for runnerscardio moves for runners
MATT RAINEY
From standing, push off right foot to jump a couple feet to the left. Land on left foot and let right foot swing behind you, speed-skater style. Quickly repeat on other side for 1 rep.

Inhaler Device Errors Common Among Health Care Providers


Healthcare providers (HCPs) lack knowledge on appropriate inhaler technique, according to a systematic review published in the May/June issue of the Journal of Allergy and Clinical Immunology: In Practice. The lack of knowledge may lead to ineffective therapy when HCPs teach patients how to use pressurized metered-dose inhalers or dry powder inhalers for the management of respiratory conditions.
“These results highlight the urgent need to design efficient strategies to improve the training of [HCPs] in the appropriate use of inhalers,” write lead author Vicente Plaza, MD, PhD, from the Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, and colleagues.
The authors reviewed studies that assessed inhaler technique among HCPs and were published between January 1975 and December 2014. They identified 404 studies, of which 55 met the inclusion criteria and were included in the analysis. These included data on 6034 HCPs across a variety of disciplines, with a total of 9993 tests of the inhaler technique performed.
Overall, inhaler technique was considered correct in only 15.5% of cases (95% confidence interval [CI], 12% – 19.3%). Moreover, the proportion declined significantly from the early study period (defined as 1975 to 1995) to the later part (1996 to 2014), going from 20.5% (95% CI, 14.9% – 26.8%) to 10.8% (95% CI, 7.3% -14.8%).
Further, the authors found that two of the most common errors (lack of coordination and forceful rapid inhalation) were considered critical errors based on previous study findings because of “their association with uncontrolled asthma and/or increased rates of exacerbations.”
When compared with a previous study assessing inhaler technique among 54,354 patients, Plaza and colleagues note “HCPs correctly performed [inhaler technique] only half as often as patients did (15.5% vs 31%, respectively)” and that the mean inhaler technique error rates across various devices “were notably higher among HCPs and similar to the rates that would be expected from a treatment-naive subject using an inhaler for the first time.”
The study authors acknowledge that the heterogeneity of the study groups, as well as the inability to appropriately assess the risk of bias across all studies, was a potential limitation.
“Patient training and education in the use of inhalers is an essential part of the tasks of HCPs involved in the care of chronic respiratory patients, including physicians, respiratory therapists, nurses, and pharmacists,” Plaza and colleagues write.
“It is likely that specific and repeated — a key element — educational programs addressed to HCPs according to their needs could improve [inhaler technique] among those professionals, thus leading to greater success in instructing patients in proper inhaler use,” they conclude.
No funding was received for this study. The authors have disclosed no relevant financial relationships.
J Allergy Clin Immunol Pract. 2018;6:987-995. Abstract